We are pleased to announce the appointment of Scott Huntington, MD, MPH, MSc, Associate Professor of Medicine (Hematology), as Chief Quality Officer for Smilow Cancer Hospital and Yale Cancer Center, effective January 1, 2024. Dr. Huntington is a leader in health services research and care delivery. A nationally recognized lymphoma expert, he brings deep clinical expertise and perspective to his new role. As Chief Quality Officer he will build on the impressive record in performance improvement that he facilitated while serving as Firm Chief on our ambulatory NP7 unit and inpatient NP11 floor over the past several years.
More recently, Dr. Huntington has served as Interim Quality Officer since July 2023 and he quickly made a positive impression on our work at Smilow Cancer Hospital. In collaboration with our Quality and Safety team, Dr. Huntington has made substantial contributions over the past few months. Among other areas, he has focused on inpatient chemotherapy utilization, improved analysis of adverse events, and optimization of end of life care. He will continue to work closely with the Smilow leadership team, as well as our physicians, nurses, and staff to monitor and optimize our current practices and implement organizational system changes for quality improvement across all Smilow Cancer Hospital locations.
“Dr. Huntington is a remarkable physician leader and a clinical role model, and I am thrilled to have him step into this position. He is committed to serving both our patients and our clinical teams across the cancer care enterprise. Please join our leadership team in congratulating Dr. Huntington on his new role,” said Kevin Billingsley, MD, MBA, Chief Medical Officer for Smilow Cancer Hospital and Yale Cancer Center.
Prior to joining Yale, Dr. Huntington completed his hematology-oncology training and received a Master of Science in Health Policy Research at the University of Pennsylvania. He serves as an investigator on clinical trials evaluating novel cancer therapeutics and is an active member of Yale’s Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, where he leads research focused on improving the delivery of complex cancer treatment during routine care.